• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dicerna bails on EnCore lipid nanoparticle tumor delivery program

September 27, 2016 By Sarah Faulkner

Dicerna PharmaceuticalsDicerna Pharmaceuticals (NSDQ:DRNA) said yesterday that it plans to spike the development program for its lipid nanoparticle delivery system for solid tumors because its preliminary results don’t meet expectations.

The Cambridge, Mass.-based company evaluated its lipid nanoparticle, DCR-MYC, in a pair of clinical trials – a Phase I study of patients with solid tumors, hematological malignancies and pancreatic neuroendocrine tumors; and a Phase Ib/II trial of patients with hepatocellular carcinomas. Tumor biopsies taken pre- and post-treatment showed proof of concept for the nanoparticle as a drug delivery system, but the therapy’s efficacy was less than expected, according to Dicerna.

The company said it will focus its resources on its GalXC technology platform to advance candidates for therapeutic areas like rare disease and chronic liver diseases.

“Based on the performance of the GalXC platform, the strength of the preclinical data and the broad therapeutic opportunities for RNAi in liver-targeted diseases, we are prioritizing resources to advance the product candidates emerging from this platform,” president & CEO Douglas Fambrough said in prepared remarks. “Discontinuing our DCR-PH1 and DCR-MYC lipid nanoparticle programs allows us to focus our resources on efficiently developing our GalXC product candidates and building on the solid scientific foundation in RNAi that Dicerna has developed over the past decade. We greatly appreciate the participation of all of the patients, families and clinical investigators in the DCR-PH1 development program, as their contributions provided important insights into the primary hyperoxaluria disease state, which will guide the development of DCR-PHXC.”

DRNA shares were trading at $4.18 apiece in mid-morning activity today, down -2.11%.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Nanoparticles, Oncology Tagged With: Dicerna Pharmaceuticals

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS